Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

25.64 -0.16 (-0.62%)
Delayed Quote Updated: 10:01 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
There are always stocks to buy if you're Ark Invest's ace stock picker. 
Via The Motley Fool
News headline image
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
3 Personalized Medicine Stocks to Buy for Long-Time Returns ↗
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out. 
Via InvestorPlace
News headline image
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies: Q1 Earnings Insights ↗
 
Via Benzinga
What To Know About Piper Sandler's Upgrade of Adaptive Biotechnologies ↗
 
Via Benzinga
Looking Into Adaptive Biotechnologies's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platform 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Luminar Technologies, EHang Holdings And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Earnings Scheduled For February 14, 2023 ↗
Companies Reporting Before The Bell • WESCO International (NYSE:WCC) is projected to report quarterly earnings at $3.79 per share on revenue of $5.37 billion. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical... 
Via Benzinga
News headline image
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
From Adaptive Biotechnologies
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.